Age (years) | ER+/HER2- | ER+/HER2+ | ER-/HER2+ | Triple- | Luminal A | Luminal B |
---|
20–39 | 97 | 19 | 30 | 28 | 23 | 67 |
40–49 | 189 | 33 | 30 | 31 | 64 | 96 |
50–59 | 146 | 18 | 27 | 26 | 39 | 57 |
60+ | 110 | 9 | 22 | 22 | 30 | 48 |
All (%) | 542 (64.8) | 79 (9.4) | 109 (13.0) | 107 (12.8) | 156 (27.4)* | 268 (46.8)* |
Ave age | 49.7 ± 11.7 | 46.2 ± 11.0a
| 47.3 ± 10.4 | 48.8 ± 13.2 | 49.7 ± 10.7b
| 47.6 ± 11.3 |
Ki67 | 26.1 ± 18.6 c
| 39.9 ± 21.0 | 43.1 ± 23.0 | 56.6 ± 26.5 c
| 11.6 ± 5.0 | 37.9 ± 18.4 |
- Legend: *Luminal A and luminal B are derived from ER+/HER2- and ER+/HER2+ tumors that had Ki67 testing with the percentages being extrapolated to the sum of all subtypes. The number of luminal A and Luminal B tumors (n = 424) does not correspond to the number of ER+/HER2- and ER+/HER2+ tumors (n = 621), because not all of the later had Ki67 testing. The age of ER+/HER2+ patients is significantly different than ER+/HER2- patients (P < 0.01)a. The age of luminal A patients is significantly different than luminal B patients (P = 0.04)b. The Ki67 of ER+/HER2- and triple- breast cancers are significantly different than other subtypes (P < 0.001)c